Novel anti-inflammatory effects of canagliflozin involving Hexokinase II in lipopolysaccharide-stimulated human coronary artery endothelial cells
Vascular inflammation and disturbed metabolism are observed in heart failure and type 2 diabetes mellitus. Glycolytic enzyme hexokinase II (HKII) is upregulated by inflammation. We hypothesized that SGLT2 inhibitors Canagliflozin (Cana), Empagliflozin (Empa) or Dapagliflozin (Dapa) reduces inflammat...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2021
|
| In: |
Cardiovascular drugs and therapy
Year: 2021, Volume: 35, Issue: 6, Pages: 1083-1094 |
| ISSN: | 1573-7241 |
| DOI: | 10.1007/s10557-020-07083-w |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1007/s10557-020-07083-w Verlag, kostenfrei, Volltext: https://link.springer.com/article/10.1007/s10557-020-07083-w |
| Author Notes: | Laween Uthman, Marius Kuschma, Gregor Römer, Marleen Boomsma, Jens Kessler, Jeroen Hermanides, Markus W. Hollmann, Benedikt Preckel, Coert J. Zuurbier, Nina C. Weber |
| Summary: | Vascular inflammation and disturbed metabolism are observed in heart failure and type 2 diabetes mellitus. Glycolytic enzyme hexokinase II (HKII) is upregulated by inflammation. We hypothesized that SGLT2 inhibitors Canagliflozin (Cana), Empagliflozin (Empa) or Dapagliflozin (Dapa) reduces inflammation via HKII in endothelial cells, and that HKII-dependent inflammation is determined by ERK1/2, NF-κB. and/or AMPK activity in lipopolysaccharide (LPS)-stimulated human coronary artery endothelial cells (HCAECs). |
|---|---|
| Item Description: | "Published online: 13 October 2020".- S. 1083 Gesehen am 23.09.2024 |
| Physical Description: | Online Resource |
| ISSN: | 1573-7241 |
| DOI: | 10.1007/s10557-020-07083-w |